These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 6432393)

  • 21. Mass spectrometric measurements of norepinephrine synthesis in man from infusion of stable isotope-labelled L-threo-3,4-dihydroxyphenylserine.
    Suzuki T; Sakoda S; Ueji M; Kishimoto S
    Life Sci; 1985 Feb; 36(5):435-42. PubMed ID: 3918223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Result of long-term administration of L-threo-3,4-dihydroxyphenylserine in patients with pure akinesia as an early symptom of progressive supranuclear palsy.
    Yamamoto M; Fujii S; Hatanaka Y
    Clin Neuropharmacol; 1997 Aug; 20(4):371-3. PubMed ID: 9260736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A comparative study of the effect of bromocriptine and pergolide on Parkinson disease].
    de Yébenes JG; García-Ruiz PJ; Sánchez-Pernaute R
    Rev Neurol; 1997 Sep; 25(145):1343-5. PubMed ID: 9377286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients.
    Maruyama W; Naoi M; Narabayashi H
    J Neurol Sci; 1996 Jul; 139(1):141-8. PubMed ID: 8836986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amelioration of frozen gait by tandospirone, a serotonin 1A agonist, in a patient with pure akinesia developing resistance to L-threo-3,4-dihydroxyphenylserine.
    Miyata S; Hamamura T; Yoshinaga J; Nakamura Y; Imamura T; Hikiji A; Kuroda S
    Clin Neuropharmacol; 2001; 24(4):232-4. PubMed ID: 11479395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pure akinesia: an atypical manifestation of progressive supranuclear palsy.
    Matsuo H; Takashima H; Kishikawa M; Kinoshita I; Mori M; Tsujihata M; Nagataki S
    J Neurol Neurosurg Psychiatry; 1991 May; 54(5):397-400. PubMed ID: 1865200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [L-5-hydroxytryptophan(L-5-HTP) therapy of Parkinson's disease. 2].
    Sano I; Taniguchi K
    Munch Med Wochenschr; 1972 Oct; 114(40):1717-9. PubMed ID: 4538893
    [No Abstract]   [Full Text] [Related]  

  • 28. [Synthesis of norepinephrine from 3,4-dihydroxyphenylserine by L-aromatic amino acid decarboxylase of the rat brain and kidneys].
    Fujiwara H; Inagaki C; Ikeda Y; Tanaka C
    Nihon Yakurigaku Zasshi; 1976 Oct; 72(7):891-8. PubMed ID: 14060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three types of akinesia in the progressive course of Parkinson's disease.
    Narabayashi H
    Adv Neurol; 1993; 60():18-24. PubMed ID: 8093577
    [No Abstract]   [Full Text] [Related]  

  • 30. [Levodopa as a single treatment of Parkinsonism. Long-term control of 24 cases with discrimination analysis].
    Borromei A; Manzini A
    Minerva Med; 1974 Nov; 65(79):4160-70. PubMed ID: 4610450
    [No Abstract]   [Full Text] [Related]  

  • 31. [Study on the metabolism of droxidopa in humans].
    Maruyama W; Naoi M; Narabayashi H
    Rinsho Shinkeigaku; 1994 Oct; 34(10):991-5. PubMed ID: 7834960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical effects of oral L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in patients with Shy-Drager syndrome].
    Senda Y; Muto T; Matsuoka Y; Takahashi A; Sobue I
    Rinsho Shinkeigaku; 1987 Mar; 27(3):300-4. PubMed ID: 3111772
    [No Abstract]   [Full Text] [Related]  

  • 33. [Treatment of Parkinson's disease with L-dopa. 77 cases].
    Boudin G; Castaigne P; Lhermitte F; Beck H; Guillard A; Marteau R; Pepin B; Rondot P; Raphy B
    Rev Neurol (Paris); 1970 Feb; 122(2):89-102. PubMed ID: 4931719
    [No Abstract]   [Full Text] [Related]  

  • 34. Primary progressive freezing gait.
    Achiron A; Ziv I; Goren M; Goldberg H; Zoldan Y; Sroka H; Melamed E
    Mov Disord; 1993 Jul; 8(3):293-7. PubMed ID: 8341293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parkinson's disease: a clinical review.
    Lieberman AN
    Am J Med Sci; 1974 Feb; 267(2):66-80. PubMed ID: 4821328
    [No Abstract]   [Full Text] [Related]  

  • 36. Early detection of L-dopa response in parkinsonian patients with a standardized tracking test.
    Albani C; Buck A
    Adv Neurol; 1993; 60():386-9. PubMed ID: 8420158
    [No Abstract]   [Full Text] [Related]  

  • 37. Zotepine reversibly induces akinesia and rigidity in Parkinson's disease patients with resting tremor or drug-induced psychosis.
    Arnold G; Trenkwalder C; Schwarz J; Oertel WH
    Mov Disord; 1994 Mar; 9(2):238-40. PubMed ID: 7910949
    [No Abstract]   [Full Text] [Related]  

  • 38. Parkinson's disease, cerebral arteriosclerosis, and senile dementia. Clinical features and response to levodopa.
    Parkes JD; Marsden CD; Rees JE; Curzon G; Kantamaneni BD; Knill-Jones R; Akbar A; Das S; Kataria M
    Q J Med; 1974 Jan; 43(169):49-61. PubMed ID: 4822972
    [No Abstract]   [Full Text] [Related]  

  • 39. [Inhibition of harmaline induced tremor by L-threo-3, 4-dihydroxyphenylserine, an L-norepinephrine precursor].
    Yamazaki M; Ikeda Y; Ishikawa M; Inagaki C; Tanaka C
    Nihon Yakurigaku Zasshi; 1976 Apr; 72(3):363-9. PubMed ID: 986992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impaired activity of the supplementary motor area in akinetic patients with Parkinson's disease. Improvement by the dopamine agonist apomorphine.
    Rascol OJ; Sabatini U; Chollet F; Montastruc JL; Marc-Vergnes JP; Rascol A
    Adv Neurol; 1993; 60():419-21. PubMed ID: 8420165
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.